Metformin Protects ARPE-19 Cells from Glyoxal-Induced Oxidative Stress
Open Access
- 10 July 2020
- journal article
- research article
- Published by The Endocrine Society
- Vol. 2020, 1740943
Abstract
The protective effects and mechanisms of metformin against oxidative stress were evaluated bothin vivoandin vitro. ARPE-19 cells comprised the normal group, the glyoxal-treated group (0.5 mM glyoxal), and the glyoxal+metformin group (0.5 mM glyoxal and 0.1 mM metformin). In thein vitromodel, differences in cell viability, ROS production, NO products, cellular apoptosis, and the expressions of phospho-AMPK alpha, total-AMPK alpha, Sirt1, Nrf2, TXNIP, ZO-1, and Occludin were assessed. In the glyoxal-treated group, cell viability and NO production were decreased, while ROS production and cell apoptosis were increased (p<0.05), compared with the control group. These changes were prevented by metformin treatment. Protein expressions of phospho-AMPK alpha, Sirt1, TXNIP, ZO-1, and Occludin, but not Nrf2, were decreased significantly in the glyoxal-treated group compared to normal controls. Metformin treatment significantly increased the above protein expressions and slightly increased TXNIP expression. Immunofluorescence showed that metformin prevented the glyoxal-induced, disorganized tight junctions in ARPE-19 cells. To confirm metformin's protection, Sprague-Dawley rats were injected intravenously with sodium iodate (SI) to induce oxidative stress in the retinal pigment epithelium (RPE). Metformin was then delivered intraperitoneally or intravitreally. One day and three days after SI and metformin treatments, the RPE-Bruch's membrane-choriocapillaris complex was isolated and immune-stained with ZO-1 antibodies. The morphology of the RPE showed enlarged cellular bodies and disorganized ZO-1 staining in SI-treated rats. Metformin treatment prevented these changes. The results indicated that metformin maintained the barrier functions of RPE cells bothin vivoandin vitro. Metformin exerted its protection against oxidative stress possibly via activating AMPK/Sirt1 and increasing TXNIP. Metformin has been proposed as a candidate drug for age-related macular degeneration (AMD) by both preclinical and clinical studies. The cellular and animal models used in this study might be useful for the interpretation of the molecular mechanisms involved in the drug activity.Keywords
This publication has 49 references indexed in Scilit:
- Endothelin-1 and Nitric Oxide levels in exudative age-related macular degenerationJournal of Ophthalmic and Vision Research, 2015
- Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMDAutophagy, 2014
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- Thioredoxin/Txnip: Redoxisome, as a Redox Switch for the Pathogenesis of DiseasesFrontiers in Immunology, 2014
- DNA Methylation Is Associated with Altered Gene Expression in AMDInvestigative Ophthalmology & Visual Science, 2012
- AMPK: a nutrient and energy sensor that maintains energy homeostasisNature Reviews Molecular Cell Biology, 2012
- A modified histoimmunochemistry-assisted method for in situ RPE evaluationFrontiers in Bioscience-Elite, 2012
- Age Related Changes in NAD+ Metabolism Oxidative Stress and Sirt1 Activity in Wistar RatsPLOS ONE, 2011
- Structure of mammalian AMPK and its regulation by ADPNature, 2011
- Plasma malondialdehyde and nitric oxide levels in age related macular degenerationBritish Journal of Ophthalmology, 2001